A5038447558- Urinary Bladder and Prostate Research
- Natural Products and Biological Research
- Hormonal and reproductive studies
- Pharmacology and Obesity Treatment
- Sugarcane Cultivation and Processing
- Alcohol Consumption and Health Effects
- Plant Toxicity and Pharmacological Properties
- Bee Products Chemical Analysis
- Acute Ischemic Stroke Management
- HIV/AIDS drug development and treatment
- Pharmacological Effects and Toxicity Studies
- Venous Thromboembolism Diagnosis and Management
- Immunotoxicology and immune responses
- Estrogen and related hormone effects
- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Healthcare Systems and Practices
- Reproductive Physiology in Livestock
- Neurological and metabolic disorders
- Monoclonal and Polyclonal Antibodies Research
- Peroxisome Proliferator-Activated Receptors
- Salivary Gland Tumors Diagnosis and Treatment
- Diagnosis and Treatment of Venous Diseases
- Cancer Treatment and Pharmacology
- Meat and Animal Product Quality
Duran i Reynals Hospital
2025
Institut d'Investigació Biomédica de Bellvitge
2025
McMaster University
2024
Population Health Research Institute
2024
University of Geneva
2011
Cuban Neuroscience Center
2007-2011
Centro Nacional de Investigaciones Científicas
2009-2010
Centro de Investigación Biomédica en Red
2008
Hospital Universitario de Valme
2008
Empresarios Agrupados
1998
Nimotuzumab (h-R3) is a humanized anti-epidermal growth factor receptor monoclonal antibody (mAb) registered for treating head and neck tumours. The present study was designed to evaluate the systemic skin toxicity of chronic intravenous administration h-R3 in relevant species demonstrated by comparing binding affinity constants (Kd) microsomal placental fractions from Homo sapiens Cercopithecus aethiops monkeys using an EGF-Receptor radioligand competition assay. Kd obtained were 9.1 x...
D-004 is a lipid extract of royal palm (Rosytonea regia) fruits that prevents prostate hyperplasia induced with testosterone in rodents. Previous studies have shown no D-004-related toxicity rats, but study mice had been reported. (500, 1000, and 2000 mg/kg) was evaluated subchronic (eight weeks) NMRI mice. No evidences treatment-related were detected. Thus, body-weight gain, clinical observations, food consumption, blood biochemical, hematology, organ-weight ratios, histopathological...
D-004 is a lipid extract obtained from Cuban royal palm fruits, consisting of mixture free fatty acids, that prevents prostate hyperplasia induced with testosterone in rodents. This study investigated the possible alterations due to androgen-dependent development after exposure utero and compared them those finasteride. Rats were randomized into five experimental groups: control group, three groups treated at 500, 750, or 1,000 mg/kg/day, respectively, group finasteride (10 mg/kg/day). Male...
Background: The etiology of benign prostatic hyperplasia (BPH) is not completely understood, but hormonal changes in aging men seem to be pivotal. Dihydrotestosterone, a potent, active metabolite testosterone, formed by the enzymatic action prostate 5α-reductase and causes cell growth hyperplasia. Consistent with this action, male sexual dysfunction has been clinically documented among drug-related adverse events associated inhibitors. lipidosterolic extract saw palmetto (LESP) fruit...
Abstract D-003 is a mixture of long-chain fatty acids purified from sugarcane wax that inhibits both cholesterol synthesis prior to mevalonate formation, and lipid peroxidation. has been shown prevent bone loss resorption in ovariectomized rats, significantly improves markers postmenopausal women with reduced mineral density. As hormone-replacement therapy, displays cholesterol-lowering anti-resorptive effects. We have studied its potential oestrogenic activity in-vivo using the uterotrophic...